Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | MicrobiomeTrials← Back to trialsNCT06195306
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-07-28Est. Completion: 2027-01-01
Enrollment target: 66 participants Locations- University of Kansas Cancer Center, Kansas City, Kansas, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Other microbiome trials you might be interested in
Breast Cancer
This study will explore new screening methods for early detection of breast and ovarian cancer in women at high risk for…
Bethesda, United States
Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast CarcinomaBreast Lobular Carcinoma In SituBreast Sclerosing Adenosis
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in…
Columbus, United StatesEst. completion Dec 31, 2035